<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491634</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-07-3116-AN-CTIL</org_study_id>
    <nct_id>NCT00491634</nct_id>
  </id_info>
  <brief_title>Treosulfan-based Conditioning for Transplantation in AML/MDS</brief_title>
  <official_title>Phase II Trial of Fludarabine Combined With Intravenous Treosulfan and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Chemo-refractory or Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Avichai Shimoni MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypotheses is that the introduction of dose escalated treosulfan, in substitution
      to busulfan, will reduce toxicity after allogeneic transplantation while improving
      myeloablation and and disease control in patients with AML and MDS not eligible for standard
      transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>2 years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>treatment-related mortality, GVHD, relapse, overall survival</measure>
    <time_frame>2 year after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treosulfan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treosulfan</intervention_name>
    <description>12 g/m2 x 3 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>12 g/m2 x 3</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age less than physiologic 68 years.

          2. Patients with AML and MDS not eligible for standard TBI- or Busulfan-based
             myeloablative conditioning due to age, concurrent medical condition, or extensive
             prior therapy (e.g. age &gt; 55 years for HLA-matched sibling transplants or &gt; 50 for
             matched unrelated donor transplants, prior / concomitant pulmonary, liver, or other
             organ complications).

          3. This study will only include patients with chemo-refractory disease or previously
             untreated active disease.

             A. acute myeloid leukemias (AML) according to WHO classification (&gt; 20% myeloblasts in
             peripheral blood or bone marrow at diagnosis) in induction failure, PR, untreated or
             chemo-refractory relapse. Patients must have &gt; 10% marrow blasts at the time of
             transplantation.

             B. myelodysplastic syndromes (MDS) according to WHO classification (&lt; 20% myeloblasts
             in peripheral blood and bone marrow at diagnosis), indicated for allogeneic
             transplantation:

             - refractory anaemia with excess blasts (RAEB-1 and RAEB-2) with no prior therapy

          4. Patients must have an HLA matched related or unrelated donor willing to donate either
             peripheral blood stem cells or bone marrow. Matching is based on high-resolution class
             I (HLA-A, -B, -C) and class II (HLA-DRB1, -DQB1) typing. The goal is to transplant &gt; 3
             x 106 CD34+ cells per kg body weight of the recipient -

        Exclusion Criteria:

          1. Bilirubin &gt; 3.0 mg/dl, transaminases &gt; 3 times upper normal limit

          2. Creatinine &gt; 2.0 mg/dl

          3. ECOG-Performance status &gt; 2

          4. Uncontrolled infection

          5. Pregnancy or lactation

          6. Abnormal lung diffusion capacity (DLCO &lt; 40% predicted)

          7. Severe cardiovascular disease

          8. CNS disease involvement

          9. Pleural effusion or ascites &gt; 1 liter

         10. Known hypersensitivity to fludarabine or treosulfan

         11. Psychiatric conditions/disease that impair the ability to give informed consent or to
             adequately co-operate -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>68 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Kr√∂ger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS). Bone Marrow Transplant. 2006 Feb;37(4):339-44.</citation>
    <PMID>16415898</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Avichai Shimoni MD</investigator_full_name>
    <investigator_title>Dr. Avichai Shimoni</investigator_title>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>reduced-intensity conditioning</keyword>
  <keyword>treosulfan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

